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Abstract The calcium channel blockers (CCBs) are a
diverse group of antihypertensive medications with vari-
able pharmacokinetics and clinical effects. Although
CCBs have been widely applied to the treatment of hy-
pertensive children, data regarding the pharmacokinetics,
efficacy and safety of these agents in children are ex-
tremely limited. In this review we briefly summarize the
mechanism of action of CCBs and then summarize perti-
nent pharmacokinetic information on each of the CCBs
commonly used in children, including amlodipine, dilti-
azem, felodipine, isradipine, intravenous nicardipine, ni-
fedipine and verapamil. Clinically important drug inter-
actions and adverse effects are discussed, as well as the
potential role of CCBs in renal protection. Available pe-
diatric efficacy and safety data are summarized, and rec-
ommendations made regarding the rational use of CCBs
in the management of pediatric hypertension.
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Introduction
In recent years, several new classes of antihypertensive
agents have found increasing use in the treatment of pe-
diatric hypertension, most notably calcium channel
blocking agents (CCBs) and angiotensin converting en-
zyme inhibitors. Despite the paucity of specific pediatric
data regarding the safety and efficacy of these drugs in
children, drugs from these classes have supplanted older
agents such as diuretics and beta-blockers as first-line
therapy of pediatric hypertension, not only in clinical
practice, but also in published recommendations regard-
ing the treatment of childhood hypertension [1–3]. In
this review, we will summarize pertinent pharmacologic
and therapeutic aspects of CCBs, including pediatric data
where available, and examine the potential role of these
agents in the therapy of pediatric hypertension.
Location, structure and function 
of calcium channels
Calcium plays an essential role in many cellular process-
es throughout the body, and preservation of normal func-
tion of many types of cells depends on the maintenance
of a calcium concentration gradient across cell mem-
branes, with the extracellular calcium concentration be-
ing approximately 10,000 times greater than the intracel-
lular concentration. This concentration gradient is partic-
ularly important for contraction and relaxation of vascu-
lar smooth muscle (VSM) cells [4–7]. Among the mech-
anisms utilized by VSM and other cells to maintain this
concentration gradient, calcium channels located on the
cell membrane play a key role.
Numerous classes and subclasses of calcium channels
have been described (Table 1), with the major type of
importance with respect to hypertension being the 
L-type, or “long-acting,” voltage-sensitive calcium chan-
nel [7–12]. L-type channels are widely distributed in the
cardiovascular system, especially in the myocardium and
VSM, and are the target of all CCBs currently in clinical
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use. Of the other types of calcium channels, only the 
T-type channel has been found to have clinical impor-
tance with respect to hypertension and other cardiovas-
cular disease [5, 9, 13]. For a discussion of the other
types of calcium channels, the reader is encouraged to
consult one of the several recent reviews on this topic
[14–16].
The structure of the voltage-sensitive calcium channel
has been described in detail [4, 9–12, 17]. As illustrated
in Fig. 1, it is composed of several components, includ-
ing the ion-conducting α1-subunit, as well as several ac-
cessory subunits designated α2, β, δ and γ. These sub-
units have all been sequenced and their genes identified
[8–12]. The α1-subunit is the most important component
of the calcium channel, containing the “pore” through
which calcium ions pass, and is the binding site of all of
the CCBs currently in use. Variations in the α1-subunit
account for the differences in voltage and pharmacologic
sensitivity between the voltage-sensitive channel types
listed in Table 1 [10, 12]. The α1-subunit itself contains
several different functional regions to which the CCBs
bind, with CCBs of different classes (see below) binding
to different regions [7, 12, 17]. The α2-, β,-, δ- and 
γ-subunits primarily act to modulate the function of the
α1-subunit [12, 18]. Regulation of the entire calcium
channel itself is a function of neurotransmitters and other
hormones, primarily via second messengers such as 
G-proteins [9].
Given the large extracellular-to-intracellular concen-
tration gradient noted above, calcium will naturally tend
to enter the cell whenever a calcium channel opens. De-
polarization of the cell membrane causes a conformatio-
nal change in the calcium channel that allows extracellu-
lar calcium to enter the cell. In the case of VSM cells,
once calcium has entered the cell, a further release of
calcium from the sarcoplasmic reticulum occurs, leading
to activation of the actin-myosin complex and muscular
contraction [4, 5, 7]. Regulation of this process occurs
through a variety of mechanisms as noted above, and has
been discussed elsewhere [9, 19]. The affinity of CCBs
for their binding sites increases during membrane depo-
larization; thus, these agents prevent VSM cell contrac-
tion by interfering with calcium influx following depo-
larization. This same mechanism produces the myocar-
dial depression and negative inotropic actions of the first
generation CCBs, most notably verapamil. This effect is
much less likely to be seen with the second and third
generation dihydropyridine CCBs because of their in-
creased vascular selectivity (see below), which makes
them well suited to the treatment of hypertension.
The other major factor that may account for the effi-
cacy of CCBs in the treatment of hypertension is an al-
teration in VSM calcium homeostasis [4, 20, 21]. Al-
though a detailed discussion of this topic is beyond the
scope of this review, several alterations in intracellular
VSM calcium metabolism have been described in animal
models of hypertension, including increased calcium up-
take, decreased sodium-calcium exchange, and an in-
creased intracellular calcium content [20]. This last phe-
nomenon has a human parallel in the increased intracel-
lular calcium content of platelets from hypertensive sub-
jects. While the relationship of such experimental find-
ings to the pathogenesis of human hypertension remains
unclear at this time, it is possible that such abnormalities
of calcium metabolism could lead to a state of increased
peripheral vascular resistance [20, 21]. If true, this mech-
anism would provide a logical foundation for the incor-
poration of CCBs into antihypertensive regimens.
Table 1 Voltage-sensitive calcium channel subtypes (adapted from refs. [7, 11, 12, 15, 16, 21])
Type Voltage Distribution Major functions Blocked by
L (long-acting) High Predominantly myocardium Muscular contraction Verapamil, diltiazem 
and smooth muscle and dihydropyridine CCBs
N (neuronal) High Presynaptic nerve terminals Catecholamine release ω-Conotoxin GVIA
P (Purkinje) High Presynaptic nerve terminals, mainly Neurotransmitter release Agatoxin FTX 
in cerebellar Purkinje neurons
Q High Presynaptic nerve terminals Neurotransmitter release Agatoxin FTX
R High Neural tissue Neurotransmitter release Cadmium
T (transient) Low Postsynaptic nerve terminals and nodal Pacemaker activity Mifebradila
tissue (sinoatrial, atrioventricular)
a Withdrawn from market
Fig. 1 Subunit composition of the L-type calcium channel. See
text for descriptions of subunits. (Reprinted by permission from
ref. [12])
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Pharmacologic classification of CCBs
Since the introduction of the CCBs onto the drug market,
several classification schemes have been proposed. The
oldest and one of the most widely accepted classifica-
tions is based upon the drugs’ chemical structures. Ac-
cording to this scheme, CCBs are divided into benzo-
thiazepines, phenylalkylamines, and dihydropyridines,
exemplified by diltiazem, verapamil and nifedipine, re-
spectively [22]. (A fourth class, the tetraols, has been de-
veloped, but the only agent in this class is mifebradil,
which has been withdrawn from the market because of
drug interactions.) Another classification scheme, that of
Fleckenstein, divided CCBs into three groups, A, B, and
C, with groups A and B being inhibitors of calcium-
dependent excitation-contraction coupling, and group C
having less specific, less potent effects on excitation-
contraction coupling [23, 24]. Once the various calcium
channel subtypes were identified (Table 1), CCBs were
then classified as either “selective” or “non-selective,”
with the “selective” agents acting on the L-type slow
channels, and the “nonselective” agents acting on the L,
T, N, and P channels. Most recently, Toyo-Oka and Nayler
have identified three generations of CCBs based on
receptor binding properties, tissue selectivity, and phar-
macokinetic profiles [22, 25, 26]. Nifedipine, diltiazem,
and verapamil represent the first generation. The second
generation includes agents with increased vascular selec-
tivity, including isradipine and felodipine. Third genera-
tion agents, most notably amlodipine, are characterized
by being highly lipophilic, and have high affinity for
specific binding sites on the calcium channel, properties
which are responsible for their gradual onset of action
and prolonged duration of antihypertensive effect. This
is perhaps the most useful classification of these agents,
and is the scheme followed in this review.
Pharmacokinetics
As we have mentioned previously, the amount of pediat-
ric data available regarding the therapeutic use of CCBs
is extremely limited. The amount of pharmacokinetic da-
ta is even more limited, a problem that will need to be
addressed in the future when new drugs are studied and
marketed. Most of the data in this section will be adult
data that we will attempt to extrapolate for pediatric pur-
poses. Pertinent pharmacologic parameters are summa-
rized in Table 2. (Authors’ note: in this section of the re-
view, CCBs of interest are reviewed in alphabetical or-
der.)
Amlodipine
As will be seen from the following discussion, most 
calcium channel blockers, notably the dihydropyridine 
analogues, characteristically have low bioavailability
[10–30%] and short elimination half-lives [3–6 h]. Am-
lodipine, however, is pharmacologically distinct from the
rest of the group [27, 28]. The drug was designed in an
effort to make a compound that produced typical dihy-
dropyridine effects in vivo, but that would also exhibit
an increased absolute bioavailability and prolonged dura-
tion of effect. Thus, amlodipine has an absolute bioavail-
ability of 60–65%, with food having little effect on ab-
sorption. It has an extremely high tissue affinity and pro-
tein binding of approximately 97%, contributing to its
large volume of distribution of 21 l/kg. Mean peak serum
levels are linear and age independent: 3 ng/ml after 5 mg
and 5.9 ng/ml after 10 mg oral doses in elderly or young
healthy volunteers respectively [27, 28]. Its prolonged
duration of effect can be explained by its extremely long
elimination half-life, approximately 36 h in healthy vol-
unteers, which can increase to as long as 45 h after re-
peated administration [28]. Its lipophilic character also
leads to concentration of the drug in the lipid bilayers of
the cell membrane, leading to a depot effect that results
in sustained release of the drug to its site of action, the
calcium channel [29, 30]. As noted below, these proper-
ties make amlodipine better suited for chronic antihyper-
tensive therapy, as opposed to treatment of acute hyper-
tension.
Amlodipine undergoes extensive hepatic metabolism,
as do all CCBs. Amlodipine is oxidized to the pyridine
analogue, with subsequent oxidative deamination of the
2-aminoethoxymethyl side chain or deesterification at
the 5-methoxycarbonyl group. Several metabolites are
produced by the breakdown of amlodipine, all of which
are inactive and have no pharmacologic or therapeutic
Table 2 Pharmacokinetic parameters of selected CCBs. All data based on adult studies (IR immediate release, ER extended release)
Drug Onset of clinical effect Elimination half-life Effect of renal insufficiency
Amlodipine 6 h 35–48 h No significant effect
Diltiazem 30 min (IR) 3.2–6.6 h (IR), 5–10 h (ER) No significant effect
Felodipine 2–5 h 10–16 h Increased plasma concentrations of inactive metabolites
Isradipine 1 h 5–10.7 h Increased bioavailability in mild renal insufficiency; 
decreased bioavailability in severe renal insufficiency
Nicardipine (IV) 1 min 8.6–14.4 ha Decreased clearance in moderate renal insufficiency
Nifedipine 20 min (IR), 2–2.5 h (ER) 1.7–3.4 h (IR), 3.7–4.3 h (ER) No significant effect
Verapamil 18 min (IR) 2-7 h (IR), 6.4–12 h (ER) Decreased clearance in renal insufficiency
a Although nicardipine has a relatively long elimination half-life, when using the intravenous form, plasma concentrations will decrease
by up to 50% within 2 h following discontinuation of the infusion
peak response of 2–4 h. Mean peak serum concentrations
are 4–6 nmol/l. These concentrations produced 50% of
the maximum antihypertensive effect [43]. A correlation
exists between plasma concentrations and blood pressure
effects in healthy and hypertensive subjects. Other ef-
fects, including those on total peripheral resistance 
and forearm blood flow, are also dependent on plasma
concentrations. However, the diuretic/natriuretic effects 
of felodipine seem to be dose dependent. Doses above 
20 mg have been found to reduce both natriuresis and di-
uresis, while doses less than 20 mg seem to promote
these effects [44]. Some investigators have targeted
achieving plasma serum concentrations of 40 nmol/l, al-
though plasma concentrations above 30 nmol/l may con-
tribute to toxicity.
Similar to amlodipine, felodipine exhibits high tissue
and protein binding of approximately 99%. An interest-
ing property is that it also binds to some extent to eryth-
rocytes, contributing to approximately 30% of the total
plasma concentration [45]. The volume of distribution
ranges from 6 to 18.2 l/kg. A three-compartment model
best describes the distribution of felodipine. An initial,
rapid distribution phase with a half-life of 6.4 min repre-
sents distribution into total body water. This is followed
by a second, slower, distribution phase with a half-life of
1.6 h representing tissue reequilibration [46].
Felodipine, although completely absorbed from the
gastrointestinal tract, only has an absolute bioavailability
of about 15–20%. This is the result of extensive first-
pass metabolism rather than poor absorption. Drug ab-
sorption may also be affected by administration with
meals or grapefruit juice, as discussed later. The major
route of metabolism is the oxidation of felodipine to the
corresponding inactive purine analog [H152/37] via the
cytochrome P450–3A pathway. Then H152/37 is further
metabolized by cleavage of the methyl and ethyl ester
groups and by oxidation of the methyl groups of the py-
ridine structure to corresponding alcohols [46]. These
lead to the ten known felodipine metabolites, none of
which has significant antihypertensive effects. The elim-
ination half-life of the active compound is 10–16 h, en-
abling the drug to be dosed once daily. Metabolites of fe-
lodipine are excreted in the urine as both free acids and
as conjugates that account for 37% of the excreted
amount of the drug. Metabolites formed by aliphatic hy-
droxylation are excreted by first-order processes while
the mono-acids decline in a biphasic manner. Levels of
these metabolites may increase in renal failure (Table 2).
Felodipine is also excreted minimally [10%] in feces. It
is probably unnecessary to make dose adjustments for re-
nal failure [45]. Only about 9% of felodipine is removed
by dialysis, so supplemental doses are not needed.
One study of felodipine kinetics in children has been
reported to date by Blowey et al. [47]. Six patients (aged
9.4–16.1 years) were studied, five of whom were also re-
ceiving cyclosporine A. Kinetic parameters reported
were median tmax of 3.8 h, total plasma clearance of 
79.8 ml/min×kg–1, AUC of 747 nmol/l/h, and terminal
half-life of 21.2 h. It should be noted that patient 6, the
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activity. The rate of oxidation of amlodipine may be
slower than that of other CCBs as suggested by its less
extensive first-pass metabolism and longer elimination
half-life [31]. The drug undergoes approximately 60%
renal excretion and 5–10% appears as unchanged drug in
the urine. Another notable source of excretion is via the
feces at 20–25%. Because of its hepatic metabolism, am-
lodipine concentrations in renal failure do not seem to
increase to the point of clinical significance (Table 2),
and the dosage usually does not need adjustment or sup-
plementation during dialysis. However, as with many
CCBs, adjustment may be warranted if the patient has
extensive hepatic impairment.
Unfortunately, the studies that have been published on
amlodipine use in children have primarily focused on ef-
ficacy and safety [32–36]. While several of these studies
have suggested pharmacokinetic differences in children
compared to adults, including a need to dose the drug
twice daily to achieve adequate blood pressure control
(see below), there is still a need for formal pharmacoki-
netic studies of this drug in children.
Diltiazem
Diltiazem is a benzothiazepine derivative that in addition
to its effects on the VSM calcium channel also antagonizes
the slow channels located in the cell membrane of cardiac
muscle cells. Therefore, its primary indications are cardio-
vascular, encompassing angina, hypertension and arrhyth-
mias. Diltiazem is commercially available in several differ-
ent dosage forms, including immediate release tablets, ex-
tended release tablets, sustained release capsules and an in-
travenous form. The onset for immediate-release tablets is
30 min, with a peak response reached in 3–4 h [37]. Time
to peak concentration is approximately 2–4 h, producing
an area under the curve (AUC) of 535–685 ng/h/ml after a
90-mg immediate-release dose. The extended-release prod-
uct reaches peak response in 3–6 h and peak concentration
in 6–11 h [38]. Both the extended-release tablets and sus-
tained-release capsules must be swallowed whole in order
to achieve a sustained antihypertensive effect. Bioavail-
ability of diltiazem is approximately 35–40% and is not
greatly affected by food [39]. Diltiazem is 77–93% protein
bound, with 35–40% being bound to albumin [40, 41]. The
drug is extensively hepatically metabolized, with elimina-
tion half-lives of 3.2–6.6 h and 5–10 h for the immediate-
release and extended-release formulations, respectively
[37]. The pharmacokinetics of diltiazem is unaffected by
renal insufficiency, but both bioavailability and elimination
half-life are increased in patients with cirrhosis [38]. As
discussed below, intravenous diltiazem is primarily indicat-
ed for the treatment of arrhythmias [42], so its kinetics will
not be discussed in this review.
Felodipine
Felodipine is only available as an extended release pro-
duct that has an initial onset of action of 2–5 h, with a
only child not receiving cyclosporine A, had a markedly
shorter terminal half-life of 7.2 h and a significantly low-
er AUC of 280 nmol/l/h [47]. The values from this pa-
tient may better reflect the expected values for a pediat-
ric patient with isolated hypertension.
Isradipine
Isradipine is available as an immediate-release or ex-
tended-release product. Isradipine is rapidly and almost
completely absorbed from the gastrointestinal tract after
single dose oral administration. However, due to exten-
sive first-pass metabolism, the estimated bioavailability
of orally administered isradipine is just 14–24%. Bio-
availability is unaffected by administration with food but
may be altered in renal insufficiency (Table 2). The ini-
tial response to isradipine occurs in approximately 1 h,
producing a peak response in 2–3 h [48]. The duration of
action in adults is normally 12 h; however, full therapeu-
tic response is usually not seen until the 2nd week of
therapy. After administering 2.5–10 mg isradipine to
normal subjects, the maximum plasma concentrations
were 2.1–8.39 ng/ml, respectively. Peak plasma concen-
tration is usually reached in 1.3–3 h after administration
of the immediate release product [49, 50].
Similar to the previous two agents, isradipine exhibits
high protein binding of 95–97.4%. It is bound predomi-
nately to α1-acid glycoprotein, serum albumin and lipo-
proteins and binding is independent of pH. Isradipine un-
dergoes hepatic metabolism via the P450 system involv-
ing deesterification and aromatization of the dihydropy-
ridine moiety to yield pharmacologically inactive pyri-
dine and carboxylic acid derivatives [51]. None of the
metabolites has any therapeutic effect. The volume of
distribution ranges from 69 to 191 l. Isradipine exhibits a
biphasic elimination half-life, producing an alpha half-
life of 1–2 h and a terminal half-life of 8 h [48]. Renal
excretion accounts for 60–65% of elimination, and the
drug is not dialyzed to any appreciable extent. There is
no need for dose adjustment in patients with renal fail-
ure, or for supplementation in dialysis patients. The pe-
diatric studies reported to date [52, 53] on the use of this
drug have not included kinetic data.
Nicardipine
Given the absence of reports of oral nicardipine use in
children, in this review we will only discuss the intrave-
nous formulation. Based on adult data, the initial onset
of nicardipine given intravenously occurs within 1 min,
producing a reduction of 30% in mean arterial blood
pressure and a 13–26% increase in heart rate [54, 55].
The duration of action after a single intravenous dose is
approximately 3 h. Approximately 95% of nicardipine is
bound by serum proteins, specifically α1-acid glycopro-
teins (AAG), albumin, and lipoproteins. Like felodipine,
nicardipine also binds to erythrocytes. The binding of 
nicardipine to albumin, AAG, and lipoproteins is ex-
tremely pH dependent. If the serum pH increases, so
does the fraction of non-ionized or free nicardipine.
Therefore protein binding also increases due to the in-
creased availability of free nicardipine (eventually reach-
ing saturation). This increase in binding affinity has been
related to a change in the conformation of albumin (the
neutral-base transition) which occurs in this pH range
[56]. The increase in binding is related to a displacement
of the ionization equilibrium favoring the lipid-soluble
form of nicardipine. Changes in the serum concentration
of AAG and albumin have been noted in patients with
certain disease states, such as cancer, inflammation and
sepsis. These patients characteristically have increased
levels of AAG and decreased amounts of albumin, which
may lead to alterations in nicardipine pharmacokinetics
in patients with these conditions. However, it is probably
unnecessary to automatically adjust the dose of nicardi-
pine when treating such patients; its rapid onset of effect
means that the dose can be easily and quickly titrated to
the desired clinical response no matter what the underly-
ing condition.
Following infusion, nicardipine plasma concentra-
tions decline triexponentially, with a rapid early distribu-
tion phase (half-life of 2.7 min), an intermediate phase
(half-life of 44.8 min), and a terminal phase (half-life of
14.4 h) that can only be detected after long-term infu-
sions. The elimination half-life in adults is 8.6 h on aver-
age [57]. We would expect this to be much shorter in a
pediatric patient; however, there are no pediatric phar-
macokinetic data at this time to prove or disprove this
assumption. The volume of distribution is approximately
8.3 l/kg. Rapid dose-related increases in nicardipine
plasma concentrations are seen during the first 2 h after
initiation of an infusion. The concentrations reach steady
state at approximately 24–48 h. Upon termination of the
infusion, plasma concentrations rapidly decline, with at
least a 50% decrease during the first 2 h [57]. Nicardi-
pine undergoes extensive hepatic metabolism via the
P450 pathway. Transformation of the N-benzyl side-
chain position 3 is the primary site of breakdown. Oxida-
tion to the pyridine analog is also another source of me-
tabolism. The principal metabolic routes would seem to
be the major urinary alcohol metabolites S14 and S16
excreted as glucuronides [56]. Virtually no unchanged
drug is found in the urine. Although nicardipine is prin-
cipally metabolized by the liver, lower clearance has
been reported in patients with renal impairment [57], so
it is probably prudent to be more conservative in using
the drug in such patients. Obviously the dose should be
adjusted in severe hepatic impairment.
Nifedipine
Currently nifedipine is available both as an immediate-
release and as an extended-release product. Bioavaila-
bility is similar for both formulations, approximately
52–56% [58]. The immediate-release product if used
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should be taken without food due to possible reduced
peak plasma concentrations and prolonged drug action
time when administered with meals. The extended-
release product, however, is not affected by food, and
can be taken without respect to meals. The initial re-
sponse after an immediate-release dose occurs in 20 min,
with duration of 4–8 h. Peak concentration is reached in
20–45 min [59]. With the extended-release product, a bi-
phasic peak concentration occurs related to the release of
drug from the tablet matrix. The first peak occurs at
2–2.5 h, which produces the highest plasma concentra-
tion, then the second, lower peak follows 6–12 h after
the dose was administered [60]. The reported duration of
the extended-release tablet is approximately 24 h; how-
ever, more frequent dosing has been reported in pediatric
patients [61, 62]. The explanation for this is unknown
and is deserving of further study.
Nifedipine is 90–96% protein bound, which is de-
creased slightly [92–93%] in renal or hepatic impairment
[63]. Interestingly, nifedipine is also extensively distrib-
uted to the placenta, and placental transfer occurs in
some patients. The elimination half-life for the immedi-
ate release capsules is 1.7–3.4 h, for the biphasic extend-
ed-release tablet 3.7–4.3 h. Nifedipine undergoes signifi-
cant hepatic metabolism via the cytochrome P450 (CYP)
3A4 enzyme system, with the majority oxidized to a free
acid and a smaller fraction converted to a lactone. Twen-
ty to 30% of the drug is removed from the portal blood
supply by the liver due to first-pass metabolism. Intesti-
nal wall metabolism also contributes greatly to the first-
pass effect. Greater than 90% of a dose of nifedipine is
excreted in the urine as inactive metabolites, with most
urinary excretion occurring within the first 24 h. Only
trace amounts of active drug appear in the urine [60]. 
Nifedipine dosage should be reduced in patients with he-
patic impairment, and also in south Asians, who exhibit
a slower metabolism of the drug, reflecting a longer ter-
minal half-life of 8.6 h. As noted below, some data exist
regarding the use of immediate-release nifedipine cap-
sules for acute hypertension in children; however, no
pharmacokinetic studies of this agent have been conduct-
ed in children to date.
Verapamil
Verapamil is a phenylalkylamine derivative that exhibits
vasodilatory and antiarrhythmic effects, similar to dilti-
azem. Verapamil, like diltiazem, is indicated for the
treatment of angina, hypertension, and arrhythmias. The
drug is available in immediate-release, extended-release,
controlled-onset extended release (COER-24) and inject-
able formulations. The immediate-release oral formula-
tion has an initial onset of effect within 18 min and
reaches peak plasma concentration in 1–2 h following
administration. The extended-release formulation reach-
es a peak response approximately in the same time peri-
od as the immediate-release formulation, although peak
concentrations are reached in 7–9 h [64].
Although absorption of an oral dose of verapamil ex-
ceeds 90%, its bioavailability is low, approximately
20–35%, because of extensive prehepatic first-pass me-
tabolism. This is true for all formulations of verapamil,
regardless of whether capsules are swallowed intact or
sprinkled onto food [64, 65]. Approximately 83–93% of
verapamil is bound by plasma proteins. Elimination half-
life of verapamil is 2–7 h, although chronic use (>12
weeks) will prolong the half-life to 6.4–12 h [66]. Of the
12 metabolites of verapamil that have been identified,
only norverapamil reaches appreciable concentrations in
plasma. However, the cardiovascular activity of norvera-
pamil is only a fraction of that of verapamil itself [64].
Approximately 70% of an oral dose of verapamil is ex-
creted as metabolites in the urine. It is recommended that
verapamil be used with caution in patients with impaired
renal function, as prolongation of the PR interval may
occur. At least one study of verapamil pharmacokinetics
in children with hypertrophic cardiomyopathy or ar-
rhythmias demonstrated decreased clearance in infants
compared to older children [67]. However, no kinetic da-




The most common therapeutic use of CCBs in children
is for the treatment of hypertension. Since the majority
of pediatric hypertension is of renal origin [2], it is im-
portant to consider the renal effects of these drugs. Such
effects can be divided into immediate effects on renal
physiology, and long-term renoprotective effects. In the
short term, CCBs decrease mesangial cell proliferation,
thereby decreasing receptor sites for angiotensin II. The
clearance of macromolecules and superoxide free radi-
cals is increased [68]. In the glomerulus, CCBs affect
primarily the afferent arteriole, with little effect on the
efferent arteriole or glomerular capillary pressure. The
dilatation of the afferent arteriole helps reduce systemic
blood pressure. Studies have demonstrated that during
treatment of patients with essential hypertension, glom-
erular filtration rate and renal plasma flow increase 
and renal vascular resistance decreases [68], leading to
changes in natriuresis and diuresis. For example, as men-
tioned above, short-term administration of felodipine has
been demonstrated to both increase and decrease natri-
uresis and diuresis, depending on the dose administered
[44]. However, most reports have indicated that patients
maintained on CCBs for chronic therapy exhibited in-
creases in sodium and water excretion that may contrib-
ute to their antihypertensive effects [69, 70].
With respect to long-term renal protection, a long-
standing area of interest has been what effect, if any,
CCBs have on proteinuria and the progression of pro-
teinuric renal diseases. The original studies were con-
ducted in proteinuric diabetic adults and demonstrated a
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reduction in proteinuria with diltiazem, but not with nife-
dipine [71]. Diltiazem’s effect was not as great as that
produced by ACE inhibitors, and seemed to be depen-
dent on blood pressure reduction as the mechanism, as
opposed to a specific effect on intraglomerular hemody-
namics [72]. Subsequent studies have confirmed that on-
ly the non-dihydropyridine CCBs reduce proteinuria, at
least in adult patients with diabetic nephropathy [73, 74].
Animal studies conducted in the remnant kidney model
have suggested that this difference may be related to a
greater deleterious effect of dihydropyridine CCBs on
renal autoregulation compared to non-dihydropyridine
CCBs [75]. In contrast to patients with diabetes, patients
with non-diabetic proteinuric renal diseases do not 
seem to benefit from treatment with non-dihydropyridine
CCBs, and should be treated with ACE inhibitors [73,
74]. However, at least one recent study has demonstrated
a beneficial effect of verapamil in proteinuric children
[76], suggesting that perhaps other forms of renal dis-
ease may also be benefited from treatment with non-
dihydropyridine CCBs. Clearly, further studies in large
numbers of patients are needed to determine whether
CCBs will play a significant role in the treatment of pro-
teinuria in children.
Another important area of study has been the renal
protective effect of CCBs in renal transplant patients also
receiving cyclosporine and/or tacrolimus [77–80]. Al-
though the exact mechanisms for the renal protective ef-
fect remain unknown, the effects of CCBs on renal he-
modynamics discussed above probably play a significant
role, especially the afferent arteriolar dilatation. Trans-
plant recipients treated with CCBs have been shown to
maintain normal sodium excretion in spite of cyclospo-
rine-induced vasoconstriction [77]. Both short- and long-
term graft function has been demonstrated to be superior
in CCB-treated transplant recipients compared to pa-
tients not treated with CCBs [78, 79]. Such benefits ap-
pear to be independent of CCB antihypertensive effects
[80]. Given these benefits, CCBs have found widespread
use in the management of hypertension in pediatric or-
gan transplant recipients [62].
Metabolism and drug interactions
As previously mentioned, most CCBs, with the excep-
tion of amlodipine, exhibit relatively low bioavailability
despite the fact that they are avidly absorbed in the gas-
trointestinal tract. This is due to extensive prehepatic
first-pass metabolism. Once reaching the liver, CCBs as
a class are metabolized via the hepatic P450 enzyme
system, specifically through the cytochrome P450 3A
subfamily. It is this extensive hepatic metabolism that
obviates the need for dose adjustment of most CCBs in
patients with renal insufficiency (see above). However,
several other important drugs are also metabolized via
the P450 system, which sets the stage for potential drug
interactions. An important example of this phenomenon
was seen with mifebradil, which was ultimately pulled
from the market because of numerous drug interactions
[81].
When discussing drug interactions, it is important to
understand if the drug causing the interaction is a hepatic
enzyme inducer or inhibitor. Enzyme induction usually
increases the amount of enzyme in the liver, resulting in
an increase in the rate of drug metabolism, ultimately de-
creasing the area under the curve and potentially de-
creasing drug efficacy. Examples of enzyme inducers are
drugs like phenobarbital, carbamazepine, rifampin, om-
eprazole, and phenytoin. On the other hand, other drugs
can be enzyme inhibitors. Most drugs inhibit metabolism
by inhibiting the hepatic mixed-function oxidase system.
The most frequently reported clinical manifestation of
inhibition of metabolism is toxicity of the inhibited drug,
due to increased plasma concentrations of the inhibited
drug. The problems resulting from enzyme inhibition
usually can be avoided if inhibition is anticipated. Exam-
ples of enzyme inhibitors are allopurinol, erythromycin,
isoniazid, ketoconazole, oral contraceptives, and val-
proic acid.
There are numerous drug interactions affecting the
P450 enzyme system, but we are only going to discuss
the most significant interactions pertinent to reported us-
es of CCBs in pediatric patients. The first one that 
deserves mention is cyclosporine A. In the study by
Pfammatter et al. of 12 children treated with amlodipine,
cyclosporine trough levels remained constant and no ad-
justments were needed [35]. However, in at least one
adult study, amlodipine was reported to increase cyclo-
sporine levels by 25–40% [82]. Other studies have not
confirmed this finding [83]. Diltiazem is also known to
increase levels of both cyclosporine and tacrolimus
[84–87], an effect that has been utilized by some investi-
gators to reduce the amount of cyclosporine adminis-
tered [84]. Verapamil and nifedipine have also been re-
ported to impair cyclosporine elimination in children
[88]. While this is a well-documented effect of verapa-
mil also seen in adults [89], nifedipine has usually been
reported not to affect cyclosporine metabolism [89, 90].
Given these conflicting reports, it would clearly be pru-
dent to closely monitor cyclosporine levels after starting
a transplant patient on any CCB.
Another interaction of note is the interaction between
the CCBs and antifungals of the azole class, fluconazole,
itraconazole, and ketoconazole. The azoles inhibit the
hepatic isoenzyme CYP3A4, which is involved in the
metabolism of several CCBs, namely nifedipine, isradi-
pine, nicardipine, amlodipine, and felodipine. This can
cause increased serum concentrations of the CCB, and
increase the risk of potential adverse effects, notably pe-
ripheral edema [91]. Felodipine also has reported drug
interactions with carbamazepine, erythromycin, pheno-
barbital and phenytoin. Erythromycin can significantly
increase the plasma concentration of felodipine, while
the other drugs mentioned have caused a diminished effi-
cacy of felodipine [45]. Conversely, diltiazem and vera-
pamil can increase carbamazepine levels, leading to po-
tential neurotoxicity [87]. Given these numerous interac-
308
309
tions, we would advise that practitioners caring for chil-
dren with complex medication regimens either consult
one of the available comprehensive reviews on the sub-
ject, or avoid those CCBs with the largest number of re-
ported interactions, especially verapamil, diltiazem and
felodipine.
Finally, it is also important to mention some issues re-
lated to the effect of food on CCB metabolism. As noted
in the preceding discussions of individual CCBs, usually
administering CCBs with food has little or no effect on
their absorption, although there are a few exceptions (see
above). The most notable drug-food interaction involv-
ing CCBs is the interaction with grapefruit juice, which
has been demonstrated to increase the bioavailability and
serum concentration of felodipine, amlodipine and other
dihydropyridine CCBs [92, 93], primarily by suppressing
the cytochrome P450 enzyme CYP3A4 found in the in-
testinal wall. This leads to a reduction in the usual first-
pass metabolism of these agents discussed above. It is
unclear at this time whether a similar effect would be
seen in children, as all studies of this interaction have
been conducted in adult subjects. In addition, whether
this interaction would have a significant effect on blood
pressure is also unknown. Given these uncertainties, it
seems reasonable to caution patients that a potentially
important interaction may exist, and that CCBs should
probably be administered with liquids other than grape-
fruit juice.
Adverse effects
In general, CCBs as a class are well-tolerated medica-
tions, with a relatively low incidence of significant ad-
verse effects [94]. Many adverse effects, including flush-
ing and headache, are more common with the immedi-
ate-release preparations of these agents and appear to be
dose related. Tachycardia is another frequently reported
adverse effect of CCBs that is intrinsically related to the
vasodilatation produced by these agents. Gingival hyper-
plasia and lower extremity edema are two unique ad-
verse effects of CCBs that warrant further discussion.
Gingival hyperplasia has been reported with several
CCBs, including amlodipine, felodipine, nifedipine, and
verapamil [94–96]. The mechanism of this phenomenon
is unknown. Incidence rates vary between the CCBs list-
ed, and appear to be lowest with amlodipine and greatest
with nifedipine. Regression has been reported following
a change in therapy from nifedipine to isradipine [97].
Lower extremity edema has also been reported with
many CCBs, with an increased incidence at higher doses.
The mechanism is thought to be related to a direct effect
of the drugs on the local vasculature, as opposed to fluid
overload [94, 98]. All the adverse effects mentioned here
have been reported in children treated with CCBs. Spe-
cific comments regarding these effects in children will
be discussed below.
Therapeutic use of CCBs in childhood hypertension
Although there have been few prospective studies of the
safety and efficacy of CCBs in children, this class of an-
tihypertensives has come into widespread use for treat-
ment of hypertension in children and adolescents, and
has been advocated for use as first-line antihypertensive
therapy in children by several authors [1, 2]. In this sec-
tion we will briefly review some of the published pediat-
ric data that are available for these agents. Table 3 lists
suggested doses for the drugs mentioned below; these
doses are based upon published data as well as the au-
thors’ personal experience.
First-generation CCBs: verapamil, diltiazem 
and nifedipine
Although the first-generation CCBs have been in clinical
use for over 15 years, little or no data exist regarding the
efficacy of either verapamil or diltiazem in the treatment
of pediatric hypertension. Most published data regarding
verapamil use in children concern patients with either
hypertrophic cardiomyopathy [99, 100] or arrhythmias
[101]. Doses utilized for these indications have ranged
from 3 to 5 mg/kg/day and appear to be well tolerated,
although effects on blood pressure were not always re-
ported. In our practice, we have occasionally utilized
verapamil as an antihypertensive at the doses suggested
in Table 2, generally with good efficacy. Concurrent
treatment with beta-blockers, especially propranolol,
should be avoided due to the possibility of prolonging
the PR interval, which may result in heart block or even
asystole [87, 102]. The availability of extended-release
verapamil in numerous dosage strengths makes this a rel-
atively convenient drug to use and titrate, although only
in children old enough to swallow the relatively large
tablets. The immediate-release verapamil tablets, howev-
er, can be crushed and made into a suspension.
For diltiazem, recently published uses in children
have included treatment of pulmonary hypertension,
muscular dystrophy and calcinosis [84, 103–106]. Re-
ported doses used for those indications have ranged from
3 to 6 mg/kg/day and appear to be well tolerated. In the
study of patients with muscular dystrophy, blood pres-
sures were reported to be lower in the diltiazem-treated
patients than in control patients by a factor of 12% for
systolic pressure and 20% for diastolic pressure. Heart
rate was slightly higher in the diltiazem group but this
difference was not significant [105]. Another study of
pediatric liver transplant recipients switched patients
from nifedipine to diltiazem and demonstrated that treat-
ment with diltiazem increased cyclosporine levels, al-
lowing for a reduction in cyclosporine dose. The investi-
gators demonstrated that renal function was stable in the
diltiazem group compared to the nifedipine group, but
did not specifically comment on diltiazem’s effect on
blood pressure [84]. Even with the limited blood pres-
sure data reported in these studies, it can be deduced that
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diltiazem is probably an effective antihypertensive agent
in children. As with verapamil, this conclusion is sup-
ported by our own experience using diltiazem in a small
number of hypertensive children. However, it should be
emphasized that because of the effects of verapamil and
diltiazem on cardiac conduction, as well as the availabil-
ity of newer compounds, these CCBs are not routinely
used in the treatment of childhood hypertension.
In contrast to verapamil and diltiazem, there is quite a
bit of published data regarding use of nifedipine for the
treatment of childhood hypertension, although one cave-
at is that this literature is confined almost exclusively to
the use of nifedipine for treatment of hypertensive emer-
gencies. An important point to make here is that al-
though the discussion that follows refers to “sublingual”
administration of nifedipine, in reality, no absorption of
the drug occurs in the mouth itself [107]; rather, it is
likely that all absorption of the drug occurs in the gastro-
intestinal tract, with “sublingual” administration leading
to more rapid onset of drug effect due to swallowing of
the drug liquid. The same effect can be produced by bit-
ing then swallowing the capsule. However, since the
term “sublingual” is so widespread in the literature, we
will use it throughout this review to refer to this method
of administration, keeping in mind that the drug actually
does not begin to lower blood pressure until after it has
been swallowed.
The first report of nifedipine use in treatment of acute
hypertension was published in 1983 by Dilmen and col-
leagues [108], who administered 0.25–0.5 mg/kg/dose of
nifedipine sublingually to 21 children with severe hyper-
tension and found that it reduced blood pressure by ap-
proximately one-third within 30 min. Duration of effect
was approximately 6 h, and reported side effects includ-
ed tachycardia and flushing. Several similar reports ap-
peared in the literature over the next several years
[109–111], all concluding that in children experiencing
hypertensive emergencies, sublingual nifedipine at doses
ranging between 0.18 and 0.5 mg/kg/dose was an effec-
tive alternative to other agents that require parenteral ad-
ministration such as hydralazine or sodium nitroprusside
[108, 109]. Of note, some investigators reported that ni-
fedipine had a shorter duration of effect than expected
[109, 110], and at least one group cautioned against the
use of nifedipine for symptomatic hypertensive emergen-
cies in favor of drugs such as labetalol which can be ti-
trated to response [111]. Despite these uncertainties,
most recent recommendations for treatment of severe hy-
pertension in children include sublingual nifedipine as a
first-line agent [1–3, 112]. The advisability of continuing
this practice in light of recent literature will be discussed
below.
Use of nifedipine for treatment of chronic hyperten-
sion in children has received less attention. In fact, we
could find no published reports of the efficacy of chronic
nifedipine treatment, except for three studies in which
hypertensive children receiving nifedipine chronically
were switched to other CCBs [61, 62, 84]. Only one of
these studies reported the mg/kg dose of nifedipine that
the patients were receiving before being switched to the
Table 3 Suggested doses for selected CCBs in children (HTN hypertension, BP blood pressure, q.d. once daily, b.i.d. twice daily,
t.i.d. 3 times per day)
Drug Starting dose Dose interval Maximum dose Comments
Amlodipine 0.1–0.3 mg/kg/dose q.d.–b.i.d. 0.6 mg/kg/day up to 20 mg/day Long acting; dose 
adjustments should be 
5-7 days apart; suspension 
may be compounded 
for infants and toddlers
Diltiazem 1.5–2 mg/kg/day t.i.d.b 6 mg/kg/day up to 360 mg/day Causes increased 
cyclosporine levels
Felodipine extended-release 0.1 mg/kg/day q.d.–b.i.d. 0.6 mg/kg/day up to 20 mg/day Tablet must be swallowed 
whole and is relatively large 
in size
Isradipine 0.05–0.15 mg/kg/dose t.i.d.–q.i.d.b 0.8 mg/kg/day up to 20 mg/day Rapidly acting; useful for 
both acute and chronic
HTN; suspension may be 
compounded for infants
and toddlers
Nicardipine intravenous 0.5–1.0 µg/kg/min Continuous 4–5 µg/kg/min Continuous BP monitoring
infusion necessary; may cause 
reflex tachycardia
Nifedipine extended-releasea 0.25–0.5 mg/kg/day q.d.–b.i.d. 3 mg/kg/day up to 180 mg/day Tablet must be swallowed
whole and is too large for 
young children
Verapamil 3–4 mg/kg/day t.i.d.b 8 mg/kg/day up to 480 mg/day Concomitant administration 
of beta-adrenergic blockers
should be avoided
a Sublingual administration of immediate-release preparation no longer recommended
b Immediate-release formulation. Extended release formulations also available that allow q.d.–b.i.d. dosing
daytime BP load on ambulatory BP monitoring. Howev-
er, nocturnal BP control was somewhat better during ni-
fedipine treatment, which the authors speculated was due
to its twice-daily dosing schedule. Doses of felodipine
were not reported on a mg-per-kg basis, but were 
approximately 23% of the doses of nifedipine required
by the same patients to achieve BP control (a second 
report by the same investigators on a subgroup of 
the patients in this study reported effective doses of
0.18–0.56 mg/kg/day [47]). The authors concluded that
felodipine provided improved blood pressure control
compared to nifedipine and also led to improved compli-
ance because of the once-daily administration. Despite
this, felodipine has not found widespread use in children,
most likely because the extended-release tablet must be
swallowed whole, making it impossible to use this drug
in infants and young children.
The CCB that appears to have found the most wide-
spread use is children is amlodipine, a lipophilic third-
generation dihydropyridine drug with a longer duration
of action than any of the CCBs discussed thus far
[27–29]. This property is illustrated by studies in adults
that have demonstrated effective blood pressure control
with amlodipine even when a “missed dose” is incorpo-
rated into the study design [114]. As discussed previous-
ly, amlodipine’s duration of action is related to the prop-
erties of the drug itself, rather than to the formulation of
the tablet (as in the extended-release formulations of
shorter-acting CCBs). Thus it should in theory retain its
long duration of effect if the tablet were crushed or
placed in suspension, making it an attractive agent for
the treatment of hypertensive children. This has led to
several reports of amlodipine in the treatment of pediat-
ric hypertension, usually in children with secondary
forms of hypertension [32–36]. Doses reported to be 
effective have varied widely, ranging from 0.09 to 
0.8 mg/kg/day (Table 3), with several investigators re-
porting that children seem to require higher doses of am-
lodipine on a per kilogram basis than those recommend-
ed for adults, with the youngest children requiring the
highest doses [32, 33, 36]. Another common finding in
the pediatric studies of amlodipine efficacy is that chil-
dren seem to require twice-daily administration of amlo-
dipine to maintain effective BP control [32, 33], as op-
posed to the once-daily administration schedule that is
utilized in adults. Whether twice-daily administration is
truly necessary because of altered amlodipine pharmaco-
kinetics in children, or whether it reflects the investiga-
tors’ prescribing habits, is a question that should hope-
fully be answered by the multicenter pediatric amlodi-
pine population pharmacokinetic study that is currently
being conducted in the United States.
We have treated over 70 children with amlodipine,
mostly patients with secondary hypertension, and have
generally found that doses of 0.1–0.6 mg/kg/day are ef-
fective and well tolerated [33]. Adverse effects have in-
cluded flushing, headache, lower extremity edema and
fatigue, and generally respond to dose reduction. Infants
and small children may be treated with amlodipine utiliz-
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alternative CCB [62]; these children were receiving
0.9±0.5 mg/kg of nifedipine per day, although it was not
specified whether they were receiving immediate-release
or extended-release nifedipine. In all three reports, pa-
tients’ blood pressures were felt to be well controlled be-
fore they were switched to the alternative agent. Despite
the lack of data, our experience and that of others is that
nifedipine in its extended-release preparation is clearly
an effective agent for chronic therapy of childhood hy-
pertension, although the large tablet size (which cannot
be crushed) limits its use to children mature enough to
be able to swallow it. Twice-daily administration may be
necessary to achieve good blood pressure control
throughout an entire 24 h-period in children [61].
Second and third generation dihydropyridine CCBs
In contrast to the first generation CCBs, a reasonably
large body of data has been published regarding the effi-
cacy of second- and third-generation CCBs in children.
Agents for which there is published efficacy data and
that have found some use in children include isradipine,
felodipine and amlodipine. Other drugs in this group that
will not be discussed here include nitrendipine, nisoldi-
pine and oral nicardipine.
One of the shortest-acting agents in this group is is-
radipine (Table 2). Data on its efficacy in pediatric hy-
pertension has been published by two groups of investi-
gators [52, 53]. Both reports demonstrated that isradipine
treatment produced significant decreases in both systolic
and diastolic blood pressure, ranging between 6–12%
and 7–17%, respectively. Doses ranged from 0.1 to 
0.8 mg/kg/day and side effects included tachycardia and
flushing. Both reports noted that isradipine had a short
duration of action, necessitating administration every
6–8 h. This is significantly different from the typical
b.i.d. regimen used in adults [51]. An extemporaneous
suspension may be compounded which has been shown
to be stable for up to 30 days [113], permitting accurate
dosing, even in infants and toddlers. An extended-release
preparation is commercially available, although it has
the disadvantage of a large tablet size. In our practice, is-
radipine has been found to be quite useful in the manage-
ment of hospitalized children with acute hypertension.
Blood pressure elevation in this setting may be relatively
unstable, necessitating more frequent dose adjustments
than usually recommended for longer-acting agents such
as amlodipine. We have also found isradipine suspension
to be extremely useful in treating infants with hyperten-
sion.
As noted above, felodipine is commercially available
only as an extended-release preparation. Its effects on
control of hypertension in children were investigated by
Moncica and colleagues, who conducted a crossover trial
of extended-release felodipine vs long-acting nifedipine
in 21 children with renal hypertension [61]. They dem-
onstrated improved BP control with once-daily felodi-
pine compared to nifedipine, as demonstrated by a lower
ing either crushed tablets [35], or by preparing an extem-
poraneous suspension [34, 115]. Amlodipine seems par-
ticularly well suited for treatment of hypertensive pediat-
ric renal transplant recipients, a group of patients in
whom CCBs are felt to have renal protective effects (see
above). In short, although some problems await more de-
tailed study, it appears as though amlodipine has de-
servedly found a place in the treatment of pediatric hy-
pertension.
Intravenously administered CCBs
Of the commercially available CCBs, three may be ad-
ministered intravenously: verapamil, diltiazem and nicar-
dipine. A class IV antiarrhythmic agent, intravenous ver-
apamil, slows conduction through the AV node, making
it suitable for treatment of atrial arrhythmias, particularly
supraventricular tachycardia [116]. Although there is one
published study demonstrating the efficacy of intrave-
nous verapamil for hypertension in adults [117], there
are no similar data available for children. Therefore, al-
though it is natural to assume that intravenous verapamil
would lower BP in hypertensive children, its effects on
cardiac conduction would suggest that it be reserved for
use as an antiarrhythmic in this age group. Intravenous
diltiazem has similar antiarrhythmic properties to vera-
pamil [42], but we could find no data regarding its use as
an antiarrhythmic in children, let alone its use as an anti-
hypertensive. Given the widespread availability of other
intravenously administered antihypertensives with dem-
onstrated efficacy in children, we cannot endorse the use
of intravenous diltiazem for this purpose.
Intravenous nicardipine has found widespread use in
recent years for the treatment of hypertensive emergen-
cies, particularly in the intensive care unit [ICU] setting.
The ideal drug for this type of hypertension would lower
blood pressure in a controlled manner, avoiding the risks
associated with sudden falls in blood pressure (see be-
low), and having little or no adverse effect on either the
underlying disease or other aspects of the patient’s clini-
cal status [118, 119]. Traditionally, sodium nitroprusside
has been the most widely used agent for hypertensive
emergencies in children, with intravenous labetalol find-
ing widespread use more recently [119]. When adminis-
tered by continuous infusion, these agents produce a
gradual, dose-related reduction in blood pressure that is
easily reversible by slowing down or discontinuing the
infusion. However, both have potentially significant side
effects, including thiocyanate buildup with prolonged
use of nitroprusside and induction of bronchospasm by
labetalol in patients with reactive airways disease.
Nicardipine has been shown to be an effective anti-
hypertensive agent in numerous studies in adults, com-
paring favorably to nitroprusside [120, 121]. Several re-
ports have now appeared regarding the use of intrave-
nous nicardipine in children with severe hypertension
[122–125]. Treluyer and colleagues reported that intrave-
nous nicardipine, administered as a continuous infusion
at a dose of 1.0 µg/kg/min, produced a reduction in sys-
tolic blood pressure of 10–13% and a reduction in dia-
stolic blood pressure of 17–26% within 1 h [122], with-
out clinically apparent side effects. Other investigators
have reported similar efficacy for intravenous nicardi-
pine in hypertensive preterm infants [123]. The effective
dose range reported by these investigators is summarized
in Table 3. In our pediatric ICU, intravenous nicardipine
has been effective in children with severe hypertension
of many causes, ranging from solid organ transplant re-
cipients to patients with respiratory failure receiving ex-
tracorporeal membrane oxygenation [125]. In contrast to
Treluyer’s report, we have found that reflex tachycardia
may indeed occur with nicardipine administration, which
is similar to data from studies in adults [54, 121]. As in
adults, this effect is usually of no clinical significance. It
should be mentioned that, as with any such patient, se-
verely hypertensive children treated with intravenous ni-
cardipine should be cared for in the intensive care setting
so that blood pressure and the effects of treatment can be
frequently monitored.
Safety concerns
Numerous concerns about the safety of CCBs have been
raised in recent years, including possible effects of CCBs
on reinfarction and mortality following acute myocardial
infarction, increased risk of bleeding, cancer and depres-
sion in patients treated with CCBs, and adverse effects
related to administration of short-acting CCBs, particu-
larly sublingual nifedipine, for treatment of acute hyper-
tension [126–130]. Although a detailed discussion of
these issues is beyond the scope of this review, many 
of the initial reports have been contradicted by later,
more carefully conducted studies and meta-analyses
[131–134], several of which have demonstrated that the
adverse cardiovascular effects of such drugs were not
seen if longer-acting CCBs were used [133, 134]. In ad-
dition, it is difficult, if not impossible, to extrapolate the
results of studies conducted in middle-aged and elderly
adults with extensive cardiovascular disease to the treat-
ment of children with isolated primary hypertension or
hypertension secondary to renal disease. Although it
would be folly to completely dismiss such safety con-
cerns, none of these data would seem to argue for avoid-
ance of CCBs in children.
However, one safety concern that does seem to war-
rant further discussion with respect to the treatment of
pediatric hypertension would be the use of sublingual ni-
fedipine for treatment of acute hypertension. Reports of
cerebrovascular accidents following sublingual nifedi-
pine use in adults with acute, severe hypertension [129,
135, 136] were followed by calls for a moratorium on
the use of this drug for this indication [130, 137]. Al-
though an informal survey of pediatric nephrologists
conducted several years ago did not support such a mor-
atorium in children [138], review of the literature reveals
several case reports of sudden, profound hypotension in
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Conclusions
Calcium channel blockers are a diverse group of antihy-
pertensive agents with significant pharmacokinetic dif-
ferences. Although the available data regarding use of
these agents in children is limited, CCBs appear to be
both effective and well tolerated in hypertensive chil-
dren, and can be utilized for the treatment of hyperten-
sion in many different clinical settings. Given the recent
developments in the United States with respect to pediat-
ric drug trials spurred by the Food and Drug Moderni-
zation Act of 1997 [148], we are hopeful that well-
designed trials of CCBs in children will be conducted in
order to answer the remaining questions regarding pedi-
atric use of CCBs.
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hypertensive children treated with sublingual nifedipine
[138–141]. Several of these children developed transient
neurologic deficits similar to those reported in adults
[138, 141]. We have seen several problems related to this
effect of sublingual nifedipine in our own institution, in-
cluding one case of severe hypotension in a liver trans-
plant recipient that could potentially have led to hepatic
artery thrombosis [142]. Furthermore, although methods
have been published for withdrawal of the liquid within
immediate-release nifedipine capsules for administration
to infants and small children [143], we have found that
the high concentration of nifedipine within the capsules
[30 mg/ml for the Procardia brand (Pratt Pharmaceuti-
cals Division, Pfizer Inc., New York, NY) 10 mg cap-
sule] makes dispensing of exact doses cumbersome at
best. In addition, there are differences in this concentra-
tion according to manufacturer, which could lead to dose
errors if this difference were not recognized. For these
reasons, we have replaced sublingual nifedipine with
other agents in our own institution, typically either intra-
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Cropp, PharmD, personal communication), it is likely
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fore, while it is reasonable to raise the question regard-
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there are no data available with which to address these
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